Tachyon operates with a dedicated internal core development team and a world-class external network of expertise. We enlist the support of leading experts in their field, from pharmacology to manufacturing, and from science to clinical to work with us in a dynamic and fast-paced development environment. Tachyon selects from the best preclinical and clinical contract research organizations (CRO) and outstanding contract manufacturing organizations (CMO) to achieve one goal – advance our programs with speed, innovation, quality and scientific integrity. This highly flexible and effective model allows us to achieve our mission to bring innovative cancer drugs to patients in need as fast as possible.
FRANK PERABO, MD, PHD
Chief Executive Officer
FRANK PERABO, MD, PHD
Chief Executive Officer
Dr. Perabo is a Life Science Executive and Entrepreneur with over 20 years’ R&D experience in Pharma and Biotech. He has founded and co-founded several Biotech companies (Barricade Therapeutics, MAIA Biotechnology). He has also served as Chief Medical Officer and Executive Vice President of Development of ESSA Pharmaceuticals and Executive Director at Astellas Pharma where he was instrumental in the development and worldwide approval of XTANDI® (Enzalutamide). Dr. Perabo has a proven track record in leading successful early and late-phase clinical development programs with extensive regulatory interactions globally. Dr. Perabo obtained his medical training at the Universities of Munich, Freiburg and Bonn after graduating magna cum laude from medical school at the University of Munich, with a PhD in Cancer Biology.
CHANDTIP CHANDHASIN, PHD
VP of Program Management
CHANDTIP CHANDHASIN, PHD
VP of Program Management
Dr. Chandhasin has more than 15 years of diversified experience in the field of oncology in leading academic, industry, and health care organizations. Prior to joining Tachyon, she served as Chief Clinical Officer at Medicenna Therapeutics where she oversaw clinical programs related to data analysis, scientific communications, and in-vitro diagnostic development. Prior to that she served as the Director of Medical Affairs at ESSA Pharmaceuticals and held Program Management positions at ApoCell, Inc., Christiana Care Health Systems, and M.D. Anderson Cancer Center. Dr. Chandhasin received a Ph.D. in Molecular and Cellular Biology from Tulane University School of Medicine and completed her post-doctoral fellowship at Baylor College of Medicine.
VAN DANG, DVM, PHD
Sr Director Preclinical Science
VAN DANG, DVM, PHD
Sr Director Preclinical Science
Dr. Dang has over five years of experience managing preclinical research programs. Her expertise includes immune-oncology animal models, DNA repair mechanisms, immunology and antibody development. Dr. Dang completed her postdoctoral fellowship at Stanford University with two inventor’s patents and a first author publication for a novel treatment for Alzheimer’s disease and Down syndrome. She received both of her doctorate degrees at Michigan State University and was briefly a licensed veterinarian.
CATHY WARREN
Sr Director Clinical Operations
CATHY WARREN
Sr Director Clinical Operations
Ms. Warren has more than 20 years of experience in the clinical research industry. Her career encompasses experiences working at various pharmaceutical, clinical research organizations and small biotechnology companies. She has overseen and led global oncology studies to successful FDA submission and approval. She earned her master’s in applied science and bachelor’s degree in nursing from the University of Detroit Mercy.
ISABEL PORTER
Assoc Director, Planning Administration & Logistics
ISABEL PORTER
Assoc Director, Planning Administration & Logistics
Ms. Porter has over 15 years of combined administrative experience between healthcare and technology industries. Prior to joining Tachyon, she served as Executive Assistant at HCA Houston Healthcare. There she leveraged her analytical and organizational skills to assist in the overall operational performance of the teams she supported. At Tachyon, Isabel is leading multiple organizational development initiatives, with the goal to promote and maintain operational excellence. Isabel is a US Army veteran who served in Operation Iraqi Freedom and applies those lessons of service, dedication, and attention to detail to Tachyon’s mission.